Found: 51
Select item for more details and to access through your institution.
Impact of academic medical center access on outcomes in multiple myeloma.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 1, p. 41, doi. 10.1002/ajh.26759
- By:
- Publication type:
- Article
Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 6, p. 690, doi. 10.1002/ajh.26166
- By:
- Publication type:
- Article
Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 3, p. 491, doi. 10.1111/ejh.14032
- By:
- Publication type:
- Article
Clinical efficacy of retreatment of daratumumab‐based therapy (D2) in daratumumab‐refractory multiple myeloma.
- Published in:
- European Journal of Haematology, 2023, v. 110, n. 6, p. 626, doi. 10.1111/ejh.13942
- By:
- Publication type:
- Article
Palliative care utilization, transfusion burden, and end‐of‐life care for patients with multiple myeloma.
- Published in:
- European Journal of Haematology, 2022, v. 109, n. 5, p. 559, doi. 10.1111/ejh.13843
- By:
- Publication type:
- Article
Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM).
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 6, p. 602, doi. 10.1111/ejh.13697
- By:
- Publication type:
- Article
Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation.
- Published in:
- European Journal of Haematology, 2020, v. 105, n. 5, p. 571, doi. 10.1111/ejh.13487
- By:
- Publication type:
- Article
Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta‐analysis.
- Published in:
- European Journal of Haematology, 2020, v. 104, n. 5, p. 420, doi. 10.1111/ejh.13374
- By:
- Publication type:
- Article
Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 11, p. e2342195, doi. 10.1001/jamanetworkopen.2023.42195
- By:
- Publication type:
- Article
Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution.
- Published in:
- Acta Haematologica, 2018, v. 139, n. 1, p. 52, doi. 10.1159/000484549
- By:
- Publication type:
- Article
Immune-Mediated Neuropathies following Autologous Stem Cell Transplantation for Multiple Myeloma: Case Series and Review of the Literature.
- Published in:
- Acta Haematologica, 2017, v. 137, n. 2, p. 86, doi. 10.1159/000453390
- By:
- Publication type:
- Article
A Critical Appraisal and Targeted Intervention of the Oncology Experience in an Internal Medicine Residency.
- Published in:
- Journal of Cancer Education, 2021, v. 36, n. 6, p. 1290, doi. 10.1007/s13187-020-01766-6
- By:
- Publication type:
- Article
Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 6, p. e227, doi. 10.1016/j.clml.2024.02.006
- By:
- Publication type:
- Article
Multiple Myeloma in Young Patients: A Scoping Review.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 1, p. 15, doi. 10.1016/j.clml.2023.08.019
- By:
- Publication type:
- Article
Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma.
- Published in:
- 2022
- By:
- Publication type:
- journal article
MM-313: Carfilzomib, Cyclophosphamide, and Dexamethasone (KCd) for the Treatment of Triple-Class Relapsed/Refractory Multiple Myeloma (RRMM): A Single-Institution Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S434, doi. 10.1016/S2152-2650(21)01969-8
- By:
- Publication type:
- Article
Poster: MM-313: Carfilzomib, Cyclophosphamide, and Dexamethasone (KCd) for the Treatment of Triple-Class Relapsed/Refractory Multiple Myeloma (RRMM): A Single-Institution Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S253, doi. 10.1016/S2152-2650(21)01583-4
- By:
- Publication type:
- Article
A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 7, p. 489, doi. 10.1016/j.clml.2021.03.006
- By:
- Publication type:
- Article
Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma.
- Published in:
- 2021
- By:
- Publication type:
- journal article
A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e8, doi. 10.1016/j.clml.2017.03.014
- By:
- Publication type:
- Article
Dietary interventions, statistical power, and unanswered questions.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2024, v. 116, n. 8, p. 1404, doi. 10.1093/jnci/djae123
- By:
- Publication type:
- Article
Dietary interventions in cancer: a systematic review of all randomized controlled trials.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2024, v. 116, n. 7, p. 1026, doi. 10.1093/jnci/djae051
- By:
- Publication type:
- Article
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Performance of newer myeloma staging systems in a contemporary, large patient cohort.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01076-w
- By:
- Publication type:
- Article
Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01023-9
- By:
- Publication type:
- Article
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00985-0
- By:
- Publication type:
- Article
Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 12, p. 1, doi. 10.1038/s41408-022-00769-4
- By:
- Publication type:
- Article
Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00750-1
- By:
- Publication type:
- Article
Financial toxicity in hematological malignancies: a systematic review.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 4, p. 1, doi. 10.1038/s41408-022-00671-z
- By:
- Publication type:
- Article
Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity.
- Published in:
- Ecancermedicalscience, 2023, v. 17, n. 1551-1584, p. 1, doi. 10.3332/ecancer.2023.1558
- By:
- Publication type:
- Article
Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Hospitalization at the end of life in patients with multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease.
- Published in:
- EJHaem, 2021, v. 2, n. 4, p. 757, doi. 10.1002/jha2.275
- By:
- Publication type:
- Article
Acute Acquired Demyelinating Polyneuropathy:An Initial Presentation of Diffuse Large B Cell Lymphoma.
- Published in:
- Middle East Journal of Cancer, 2013, v. 4, n. 1, p. 35
- By:
- Publication type:
- Article
Value in Myeloma Care: Myth or Reality.
- Published in:
- Current Hematologic Malignancy Reports, 2022, v. 17, n. 6, p. 206, doi. 10.1007/s11899-022-00669-1
- By:
- Publication type:
- Article
Inclusion criteria of currently enrolling T‐cell engaging trials in multiple myeloma: Should we be focusing on lines of prior therapy?
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 1, p. e1, doi. 10.1111/bjh.18755
- By:
- Publication type:
- Article
The promise and harms of screening for plasma cell dyscrasias.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 6, p. 704, doi. 10.1111/bjh.18634
- By:
- Publication type:
- Article
Time‐to‐event surrogate end‐points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 5, p. 587, doi. 10.1111/bjh.18568
- By:
- Publication type:
- Article
Quality of end‐of‐life care in multiple myeloma: A 13‐year analysis of a population‐based cohort in Ontario, Canada.
- Published in:
- British Journal of Haematology, 2022, v. 199, n. 5, p. 688, doi. 10.1111/bjh.18401
- By:
- Publication type:
- Article
Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials.
- Published in:
- British Journal of Haematology, 2022, v. 197, n. 6, p. e86, doi. 10.1111/bjh.18102
- By:
- Publication type:
- Article
Synthetic control arms in studies of multiple myeloma and diffuse large B‐cell lymphoma.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 5, p. 1274, doi. 10.1111/bjh.17945
- By:
- Publication type:
- Article
A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors.
- Published in:
- Translational Medicine Communications, 2023, v. 8, n. 1, p. 1, doi. 10.1186/s41231-023-00137-9
- By:
- Publication type:
- Article
Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review.
- Published in:
- JNCI Cancer Spectrum, 2023, v. 7, n. 6, p. 1, doi. 10.1093/jncics/pkad100
- By:
- Publication type:
- Article
Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 4, p. e218084, doi. 10.1001/jamanetworkopen.2021.8084
- By:
- Publication type:
- Article
A Rare Cause of Hemophagocytic Lymphohistiocytosis: Fusobacterium Infection—A Case Report and Review of the Literature.
- Published in:
- 2016
- By:
- Publication type:
- Case Study
Primary Myelofibrosis Presenting as Extramedullary Hematopoiesis in a Transplanted Liver Graft: Case Report and Review of the Literature.
- Published in:
- 2016
- By:
- Publication type:
- Case Study
Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Detecting Selection Bias in Observational Studies—When Interventions Work Too Fast.
- Published in:
- 2023
- By:
- Publication type:
- Opinion
A Rare Presentation of a Rare Disease: Pulmonary Lymphomatoid Granulomatosis.
- Published in:
- Case Reports in Pulmonology, 2012, p. 1, doi. 10.1155/2012/371490
- By:
- Publication type:
- Article